Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP.
Decreased production and/or impaired action of nitric oxide (NO) play a role in the pathogenesis of atherosclerotic cardiovascular disease and erectile dysfunction (ED) in diabetic patients. Under hyperglycemic conditions, formation and accumulation of advanced glycation end products (AGE) have been known to progress, thus contributing to tissue damage in diabetes. However, effects of inhibitors of phosphodiesterase-5 (PDE-5), an enzyme that catalyzes the degradation of cyclic guanosin-monophosphate (cGMP) and subsequently blocks the actions of NO, on AGE-exposed endothelial cells remain unknown. Therefore, this study investigated whether and how vardenafil, an inhibitor of PDE-5, could block the deleterious effects of AGE on human umbilical vein endothelial cells (HUVEC). Gene and protein expression was analyzed in quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) and western blots, respectively. Intracellular formation of reactive oxygen species (ROS) was evaluated with dihydroethidium staining. AGE increased receptor for AGE (RAGE) mRNA and protein levels in HUVEC, both of which were significantly inhibited by the treatments with 30 nM vardenafil or 5 μM 8-Br-cGMP, an analogue of cGMP. Further, vardenafil reduced the AGE-induced ROS generation and subsequently inhibited up-regulation of monocyte chemoattractant protein-1 (MCP-1) mRNA levels in HUVEC. We demonstrated here for the first time that vardenafil could block the AGE-induced up-regulation of MCP-1 mRNA levels in HUVEC by suppressing RAGE expression and subsequent ROS generation via elevation of cGMP. Our present results suggest that vardenafil directly acts on endothelial cells and it could work as an anti-inflammatory agent against AGE.
Ishibashi
Yuji
Y
Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Japan.
Matsui
Takanori
T
Takeuchi
Masayoshi
M
Yamagishi
Sho-ichi
S
D015153:Blotting, Western; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000096:biosynthesis*; D006152:Cyclic GMP / Q000378:metabolism*; D042783:Endothelial Cells / Q000187:drug effects*; D020869:Gene Expression Profiling; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D007093:Imidazoles / Q000378:metabolism*; D058986:Phosphodiesterase 5 Inhibitors / Q000378:metabolism*; D010879:Piperazines / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013450:Sulfones / Q000378:metabolism; D014227:Triazines / Q000378:metabolism; D015854:Up-Regulation; D000069058:Vardenafil Dihydrochloride
C111835:CCL2 protein, human; D018932:Chemokine CCL2; D017127:Glycation End Products, Advanced; D007093:Imidazoles; D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D012333:RNA, Messenger; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D006152:Cyclic GMP
Curr Opin Investig Drugs. 2006 Nov;7(11):985-91
17117586
J Clin Pharmacol. 2003 Mar;43(3):260-7
12638394
J Am Coll Cardiol. 2008 May 27;51(21):2040-4
18498958
Eur Urol. 2003 Sep;44(3):366-70; discussion 370-1
12932938
Diabetologia. 2006 Dec;49(12):3094-9
17004092
Curr Drug Targets. 2007 Oct;8(10):1138-43
17979674
Curr Med Chem. 2008;15(2):172-7
18220772
Expert Opin Investig Drugs. 2008 Jun;17(6):855-64
18491987
J Sex Med. 2009 Mar;6 Suppl 3:203-9
19267844
J Sex Med. 2006 Mar;3(2):242-50; discussion 250-2
16490017
Curr Pharm Des. 2005;11(18):2279-99
16022668